Delisted BIO-key Regains Nasdaq Compliance, Trading Resumes July 8
BKYI sits 33% above its 52-week low of $3.1 on light trading volume (0.3× avg).
Summary
BIO-key International has successfully regained compliance with Nasdaq listing rules, with its common stock set to resume trading on the exchange on July 8, 2026. This marks a significant reversal after the company was delisted from Nasdaq in May 2026 due to non-compliance, following a 1-for-10 reverse stock split in April aimed at meeting minimum bid price requirements. Regaining a Nasdaq listing is crucial for improving investor confidence, enhancing liquidity, and attracting broader institutional interest for the micro-cap company, addressing a major risk factor previously highlighted in its filings. The company will remain under a Discretionary Panel Monitor until July 2027.
At the time of this announcement, BKYI was trading at $4.11 on OTC in the Technology sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $3.10 to $197.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.